NEW YORK, Dec. 5, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timelyinformation, WallStEquities.com has issued free tailored Stock Review on REGN, VYGR, FPRX, and VVUS which is a click away at www.wallstequities.com/registration. On Monday, December 04, 2017, US markets saw four out
On Monday, shares in Tarrytown, New York headquartered Monaco-based Regeneron Pharmaceuticals Inc. recorded a trading volume of 1.06 million shares, which was above their three months average volume of 911.52 thousand shares. The stock ended the session 1.31% higher at $378.37. The Company's shares have 3.07% on an YTD basis. The stock is trading below its 50-day moving average by 9.43%. Moreover, shares of Regeneron Pharma, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have a Relative Strength Index (RSI) of 39.28.
On December 01st, 2017, research firm Citigroup downgraded the Company's stock rating from 'Buy' to 'Neutral' while revising its previous target price from $480 a share to $380 a share. Get started with a complimentary subscription and access to the free report on REGN at: www.wallstequities.com/registration/?symbol=REGN
Cambridge, Massachusetts headquartered Voyager Therapeutics Inc.'s stock closed the day 4.22% lower at $13.83 with a total trading volume of 406,979 shares. The Company's shares have advanced 26.53% in the previous three months. The stock is trading above its 200-day moving average by 10.07%. Additionally, shares of Voyager Therapeutics, which focuses on the development of treatments for patients suffering from severe diseases of the central nervous system, have an RSI of 41.75.
On November 28th, 2017, research firm Piper Jaffray resumed its 'Overweight' rating on the Company's stock, with a target price of $28 per share. Free research on VYGR can be accessed at: www.wallstequities.com/registration/?symbol=VYGR
Five Prime Therapeutics
Shares in South San Francisco, California headquartered Five Prime Therapeutics Inc. recorded a trading volume of 293,588 shares. The stock ended yesterday's trading session 2.16% lower at $24.93. The stock is trading below its 50-day moving average by 31.66%. Furthermore, shares of the Company, which focuses on the discovery and development of immuno-oncology protein therapeutics in the US, have an RSI of 34.31.
On November 06th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $41 a share to $50 a share. Sign up today for the free research report on FPRX at: www.wallstequities.com/registration/?symbol=FPRX
Campbell, California headquartered VIVUS Inc.'s stock finished Monday's session 3.18% higher at $0.66 with a total trading volume of 924,695 shares, which was above their three months average volume of 712.06 thousand shares. The stock is trading below its 50-day moving average by 14.93%. Additionally, shares of VIVUS, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of 39.08. Wall St. Equities' research coverage also includes the downloadable free report on VVUS at: www.wallstequities.com/registration/?symbol=VVUS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----regeneron-pharma-voyager-therapeutics-five-prime-therapeutics-and-vivus-300566594.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Bladder neck incision is a surgical procedure where cuts are made in the neck of the urinary ...
Tourette syndrome (TS) is a neurological disorder wherein the affected person makes repetitive and ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...View All